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Abstract
AIM: To study the effectiveness of melatonin vs
placebo in children with functional dyspepsia (FD).

Institutional review board statement: The study was reviewed
and approved by the Children’s Mercy Hospital Institutional
Review Board.

METHODS: The study was conducted as a double
blind, randomized, placebo controlled crossover trial.
Subjects were aged 8-17 years and diagnosed with FD
based on Rome Ⅲ criteria. All subjects had failed to
respond to 4 wk of acid suppression. Subjects receive
a continuous two weeks of placebo and a continuous
two weeks of melatonin in an order blinded to the
participant and the study team. A Global Clinical Score
was obtained to assess changes in abdominal pain. Pain
was self-reported to be worse (grade 1), no change
(grade 2), moderate improvement (grade 3), good
(grade 4; minimal pain and not interfering with daily
activities), or excellent (grade 5; no pain), respectively.
A positive clinical response was defined as a grade 3 or
greater response. Subjects wore an actigraph to assess
sleep during a one week baseline period and during
each treatment period. Subjects’ sleep latency and total
sleep time were recorded throughout the duration of
the study.

Clinical trial registration statement: This study is registered at
ClinicalTrials.gov (NCT00148603).
Informed consent statement: The legal guardians of all study
participants provided informed written consent and all study
participants provided assent prior to study enrollment.
Conflict-of-interest statement: The authors have no conflicts
of interest.
Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
work non-commercially, and license their derivative works on
different terms, provided the original work is properly cited and
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/

RESULTS: Fourteen subjects were enrolled and 12
completed the study. One withdrew prior to starting both
melatonin and placebo and the other before starting
melatonin. A positive clinical response (grade 3-5) was
achieved in 42% of subjects on melatonin vs 50% of
subjects on placebo (NS). Effect size was calculated
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pineal gland, has a well-known role in regulation
of sleep-wake cycles through its sleep promoting
effects. Melatonin is commonly used to treat sleep
disturbances related to sleep-onset latency in children
and has been shown to be effective at a dose of
[5]
5 mg . Parent-reported sleep disturbances occur
in nearly half of children with FD with the most
common problems being related to sleep onset and
[6]
maintenance . These sleep disturbances are positively
associated with functional disability in FD, with this
association mediated through physical symptoms,
[6]
including pain . Thus, melatonin may be a useful
treatment in this population to decrease pain indirectly
through improvement in sleep.
Less widely recognized is melatonin’s production
in parts of the body other than the pineal gland,
such as in the digestive system and in immune cells
[7]
including mast cells . The total amount of melatonin
in the digestive tract exceeds that of the pineal gland
and blood. Melatonin is produced at high levels in
the gastrointestinal mucosa in response to food.
It exhibits a large number of biologic effects which
may be relevant to FD including both excitatory and
inhibitory effects on the enteric nervous system, antiinflammatory properties, and both anxiolytic and
[8-10]
antidepressant effects
. At pharmacologic doses,
melatonin delays gastric emptying, in part acting as a
[10]
partial 5-HT antagonist . Thus, melatonin may also
have a direct impact on visceral sensitivity.
One study of melatonin in adult patients with
irritable bowel syndrome (IBS), another functional
gastrointestinal disorder which shares common
pathophysiologic mechanisms with FD, provides
[9]
support for this secondary pathway of action . In
this study, two weeks of treatment with melatonin
resulted in decreased mean abdominal pain scores
and an increased mean rectal pain threshold without
[9]
influencing sleep, anxiety, or depression scores . To
date, melatonin efficacy has been demonstrated in
[8]
reducing pain in adults with FD in a single study .
Specifically, twelve weeks of melatonin (5 mg taken
at bedtime) resulted in complete resolution of pain
in 56.6% of patients as compared to only 6.7%
[8]
of the patients who received placebo . However,
the specific mechanism of action was not entirely
clear, given limited information provided related to
methods of measurement on key variables. Although
significant differences for complete resolution of pain
did not emerge until the second month of treatment,
participants receiving placebo took a significantly
larger number of “sham” pain pills, nearly doubling
those take by the melatonin group in the first month
of treatment. This would suggest that they may
have had a partial response during the first month
that was not captured by the primary measurement
strategy. Taken together, these studies suggest that
treatment with melatonin may have a beneficial
effect on pain in children with FD within a relatively
short window of time.

and revealed a Cohen’s D of 0.343 which demonstrates
a medium effect favoring placebo. A grade 4 or grade
5 response was seen in 4 patients on melatonin and 5
patients on placebo. Baseline sleep parameters were
in the healthy range with the longest sleep latency
being just over 20 min (mean 7.46 ± 8.53 min) and the
shortest sleep duration just over 7 h (mean 10.09 ± 2.72
h). The mean latency did not differ between periods of
treatment with melatonin as compared to placebo (4.48
± 6.45 min vs 3.58 ± 4.24 min; NS). The mean sleep
duration did not differ between periods of treatment
with melatonin as compared to placebo (9.90 ± 3.53 h
vs 9.41 ± 2.70 h; NS).
CONCLUSION: Melatonin does not appear to have
efficacy in relieving pain in unselected pediatric
FD. Future studies should consider FD subtypes,
pathophysiologic mechanisms, and baseline sleep
disturbances.
Key words: Melatonin; Abdominal pain; Functional
dyspepsia; Sleep latency; Sleep duration; Actigraphy
© The Author(s) 2016. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Medical therapy is limited in children with
functional dyspepsia. This creates a challenging clinical
dilemma with regards to managing their symptoms.
Melatonin has been shown to have a positive effect
on pain in adults with functional dyspepsia or irritable
bowel syndrome, independent of its effects on sleep.
To date, there have been no studies to evaluate the
effect of melatonin on abdominal pain in children.
In the current study, melatonin did not result in im
provement in abdominal pain or sleep parameters in
children with functional dyspepsia.
Zybach K, Friesen CA, Schurman JV. Therapeutic effect of
melatonin on pediatric functional dyspepsia: A pilot study. World
J Gastrointest Pharmacol Ther 2016; 7(1): 156-161 Available
from: URL: http://www.wjgnet.com/2150-5349/full/v7/i1/156.
htm DOI: http://dx.doi.org/10.4292/wjgpt.v7.i1.156

INTRODUCTION
Pediatric functional dyspepsia (FD) is defined as
persistent or recurrent pain or discomfort centered
in the upper abdomen (above the umbilicus) that
is unrelated to a change in stool frequency or form
[1]
and not exclusively relieved by defecation . It is
a common diagnosis in children with population
[1,2]
prevalence estimates of 3.5% to 27% . A number of
biologic contributors to the generation of FD have been
identified and include inflammation, electromechanical
dysfunction (e.g., altered gastric emptying) and
[3,4]
visceral hyperalgesia .
Melatonin, a hormone produced, in part, by the
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Of note, there have been only a few placebo
controlled trials of medications in children specifically
with FD. This holds true for melatonin, as well, which
has not yet been studied in children with abdominal
pain in general or with FD specifically. This paucity
of studies reflects the difficulty with conducting such
trials in children, as well as concerns regarding the
ethics of witholding treatment for prolonged periods
(during the placebo phase) in a vulnerable population.
These issues might be addressed, in part, by small
n trials which create the potential for establishing
preliminary efficacy of an intervention and establishing
benefit and feasibility of completing a similar trial with
[11]
a larger sample size . The length of treatment can
be based on the suspected mechanism of action to
minimize study duration and the associated potential
for unnecessary delay in treatment modification
if/when a treatment is found to be ineffective. In a
small n preliminary trial for FD, a cross-over design is
important to not only control for the large number of
biopsychosocial factors which may affect treatment
response but also to evaluate the effects of treatment
withdrawal, an important aspect of small n trials.
The aim of the current study was to assess the
effectiveness of melatonin vs placebo in children with
FD. The study was designed as a preliminary small n
cross-over trial to establish an anticipated effect size
from which a larger, adequately powered study could
be based if results appeared promising. The specific
study duration was selected based on previous work
in adults with IBS and FD suggesting the beneficial
impact of melatonin may be seen in as little as 2-4 wk.
Thus, a 1-mo cross-over trial was deemed appropriate
at this stage both from a scientific and ethical
perspective.

Patients were excluded if they received opiates,
tramadol, gabapentin or benzodiazepines in the 4 wk
prior to enrollment.

Methods

Melatonin and placebo were compounded by the
Children’s Mercy Hospital Investigational Drug Services
(CMH IDS) Pharmacy in liquid form. Melatonin bottles
contained 70 mg of melatonin (5 mg/dose × 14 d).
Bottles were labeled A or B and d 8-21 or d 22-35
with dosing instructions of “take 20 mL at bedtime per
measurement on dropper”.
At enrollment, each participant received both
treatment bottles and each participant was given a
sleep diary with instructions and an actigraph watch
with instruction on its usage. On D 1-7, in order to
obtain baseline sleep parameters, participants were
instructed to wear the actigraph and complete the
sleep diary (sleep latency and sleep duration each
day). On D 8-21, participants were instructed to wear
the actigraph, complete the sleep diary and take
the medication labeled “D 8-21”. On D 22, a follow
up phone call was made and a standardized history
was utilized to assign a Global Clinical Score (see
Measures). On D 22-35, participants were instructed
to wear the actigraph, complete the sleep diary and
take the medication labeled “D 22-35”. Between day
36-40, participants returned to clinic and turned in the
sleep diary and actigraph. A standardized history was
utilized to obtain a second Global Clinical Score.

Measures

Clinical response: A Global Clinical Score was
determined by interview to measure changes in
abdominal pain as follows: (1) Grade 1: Worse clinical deterioration with increasing pain intensity and/
or frequency; (2) Grade 2: No change - no increase or
decrease in pain intensity or frequency; (3) Grade 3:
Moderate improvement - partial clinical response with
definite improvement in pain, but not meeting criteria
for Grade 4 response; (4) Grade 4: Good - nearly
complete relief of symptoms with minimal residual
pain and not interfering with daily activities; and (5)
Grade 5: Excellent - complete relief of pain. A positive
clinical response was defined as a response grade of 3
or greater, with subjects dichotomized into “responders”
and “non-responders” following each 2-wk medication
trial.

MATERIALS AND METHODS
Study design

The study was conducted as a single site, double
blind, randomized, placebo-controlled crossover trial.
The study involved a one week baseline sleep data
collection period followed by four weeks of sleep
data collection and medication administration. The
four weeks of medication administration involved a
continuous two weeks of placebo and a continuous
two weeks of melatonin in an order blinded to the
participant and the study team. The study protocol
was approved by the Children’s Mercy Kansas City
Institutional Review Board. Informed parental
consent and participant assent were obtained prior to
completion of any study procedures.

Sleep parameters: Time in bed and out of bed
were taken from the sleep diaries and uploaded to
the actigraph data. Sleep latency and duration were
calculated from actigraphy data. The ActiGraph brand
accelerometry monitor watches and its accompanying
software were used for this study. The accelerometer
measures movement several times per second.
Scoring programs show activity levels for specified
time periods and determine when an individual is

Subjects

Patients ages 8-17 seen in the pediatric gastro
enterology clinic with a diagnosis of FD defined
by Rome Ⅲ criteria and persistent pain despite a
minimum of 4 wk of acid suppression were included.
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Table 1 Global clinical scores for participants on melatonin
and placebo

25

Participant
1
2
3
4
5
6
7
8
9
10
11
12

20
15
10
5
0

Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

Figure 1 Overall % of patients with each global response grade on
melatonin vs placebo.

Melatonin
1

2
1
21
41
21
11
4
3
2
4
4
11

Placebo
2
41
2
5
1
5
11
4
11
31
21
4

1

Indicates initial treatment.

asleep or awake. This methodology has been validated
in studies comparing actigraphy to polysomnography
[12,13]
(the gold standard for evaluating sleep)
.

Sleep

Baseline sleep parameters were in the healthy
range with the longest sleep latency being just over
20 min (mean 7.46 ± 8.53 min) and the shortest
sleep duration just over 7 h (mean 10.09 ± 2.72 h).
The mean latency did not differ between periods of
treatment with melatonin as compared to placebo (4.48
± 6.45 min vs 3.58 ± 4.24 min; NS). The mean sleep
duration did not differ between periods of treatment
with melatonin as compared to placebo (9.90 ± 3.53 h
vs 9.41 ± 2.70 h; NS).
Just one participant had improved sleep (50%
reduction in sleep latency and 20% increase in total
sleep time), and this was while taking melatonin.
However, this participant was classified as a nonresponder, with a clinical grade of 2 following the
melatonin treatment phase. Therefore, improved sleep
could not be correlated to improved pain in this case.

Statistical analysis

SPSS version 18 was utilized. The response rate on
melatonin was compared to placebo using Fischer’s
exact test. The mean sleep latency and sleep duration,
respectively, on melatonin vs placebo were compared
using Wilcoxon Signed Rank Test.

RESULTS
Subjects

Fourteen subjects were enrolled and 12 completed the
study. One withdrew prior to starting both melatonin
and placebo. The other withdrew after completing
placebo and before starting melatonin (this participant
did not respond to placebo). The two participants who
withdrew were not included in analysis. Fifty-eight
percent of the participants were female and 83% were
Caucasian. Patients ranged in age from 11 to 16 years
old with a mean age of 13.8 ± 1.6 years. Pain was the
predominant symptom in each patient and associated
symptoms included nausea in 67%, bloating in
42%, early satiety in 33%, and vomiting in 25%. All
participants met criteria for FD, while three participants
also met criteria for IBS.

DISCUSSION
In contrast to the previous study of FD in adults,
melatonin had no significant impact on pain in children
[8]
with FD in the current study . In fact, the study was
discontinued following interim analyses which indicated
no beneficial response of melatonin and, in fact,
appeared to favor placebo. The 50% placebo response
rate in the current study was similar to what has been
reported in other pediatric abdominal pain trials where
[14]
placebo response has generally been 32%-58% .
These discordant results may be a function of
different pathophysiologic processes being more or
less important at different ages or may be a result
of differences in study design which target different
pathophysiologic factors.
One potential differential factor relates to FD
subtyping across the lifespan. In adults, there are two
recognized FD subtypes, epigastric pain syndrome
[2]
(EPS) and postprandial distress syndrome (PDS) .
The pediatric FD criteria do not contain these subtypes.

Clinical response

A positive clinical response (Grade 3-5) was achieved
in 42% of subjects on melatonin vs 50% of subjects
on placebo (NS). Effect size was calculated and
revealed a Cohen’s D of 0.343 which demonstrates
a medium effect favoring placebo. A summary of the
post treatment pain relief grades are shown in Figure
1. Individual global clinical scores for melatonin and
placebo are shown in Table 1. Of the three patients
who also met criteria for IBS, two responded to
placebo and not melatonin. The third responded to
both.
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EPS is defined by pain or burning confined to the
epigastrium whereas PDS is defined by the presence
[2]
of early satiety and/or postprandial bloating . The
participants in the one adult FD study previously noted
consisted of patients with symptoms of EPS. EPS is
rare in pediatric FD and, in fact, none of the subjects in
[15]
our study had pain localized only to the epigastrium .
Most of the participants in the current study would
have met adult criteria for PDS. This may be important
in that it has been suggested that adults with EPS may
[16]
have altered melatonin production . Thus, differences
in response between the two studies may indicate
different mechanisms of symptom generation for EPS
as compared to PDS.
A second factor that may have led to different
results is duration of treatment. As noted previously,
we chose the treatment duration for the current
study based on initial findings in adults with IBS
and FD that suggested a treatment response of
[8,9]
melatonin could be detected in as little as 2-4 wk .
In the previous adult FD study, although a partial
response arguably was seen within the first month of
treatment, significant differences in pain resolution
did not emerge between the melatonin and placebo
[8]
groups until the second month of treatment . This
overall delay in treatment response suggests that the
observed benefits of melatonin treatment may have
been due to improvement in some factor other than
visceral hypersensitivity, possibly mediated through
improvement in sleep over time. In short, treatment
duration in our study may simply not have been long
enough to test an indirect effect of melatonin on pain
through improvement in sleep.
Third, and related to the above, is the relative
composition of samples. The adult study contained
patients with sleep disturbances and these disturbances
frequently improved or resolved with melatonin.
However, the current study utilized an unselected
group of children and adolescents presenting for
evaluation of FD who all ultimately demonstrated
sleep parameters in the normal range at baseline
and which did not change significantly on melatonin.
The composition of our sample is both a strength and
limitation for our study. On the one hand, there was
limited ability to test the impact of melatonin on pain
via a sleep improvement pathway. On the other hand,
having a group of participants without discernible sleep
problems at baseline allowed us to more clearly assess
the effects of melatonin independent from sleep, i.e.,
via a visceral hypersensitivity pathway.
In conclusion, the short-term (i.e., 2 wk) use of
melatonin does not appear to have efficacy in relieving
pain in an unselected pediatric FD population. The
strengths of our study are the cross-over design and
that we were able to study melatonin in a group of
patients without sleep disturbances so we were able to
assess efficacy independent from effects on sleep. In
contrast, we studied a relatively small population and
did not address whether melatonin might be effective

WJGPT|www.wjgnet.com

over a longer duration of treatment and/or in patients
with comorbid sleep issues. Future studies involving
melatonin may take into consideration FD subtypes
and whether melatonin has effects on specific potential
pathophysiologic factors including the presence of
inflammation, electromechanical dysfunction, or the
presence of baseline sleep disturbances.
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